Previous 10 | Next 10 |
Syneos Health (SYNH) to issue $500M of senior unsecured notes in a private offering. Net proceeds will be used for general corporate purposes. The company also intends to amend its existing senior secured credit facilities to extend the maturity date thereof to August 2024.Press release For...
MORRISVILLE, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Com...
Relief Therapeutics (RLFTF) appoints Syneos Health (SYNH), a global clinical research organization, to run the European clinical trial in severe COVID-19 induced lung injury, as well as future trials in other indications.Relief has also selected AMRI, a global contract development and manufac...
Syneos Health (SYNH) appoints Larry A. Pickett, Jr. as Chief Information & Digital Officer.Pickett most recently was the co-founder and CEO of RxDataScience, a healthcare data analytics startup based in New York City, and London. Previously, he served as CIO at Pu...
MORRISVILLE, N.C., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of Larry A. Pickett, Jr. as Chief Information & Digital Officer. Pickett will lead the global Business Te...
MORRISVILLE, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), will host an Analyst and Investor Ev...
The following slide deck was published by Syneos Health, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Syneos Health, Inc. 2020 Q3 - Results - Earnings Call Presentation
I will provide background information for my new readers. Readers will see the interim data created since my last article. Near-term binary events that should have major benefits will be outlined. First major drug candidate is scheduled for NDA filing by end of 2020. For...
Syneos Health, Inc. (SYNH) Q3 2020 Earnings Conference Call October 29, 2020 8:00 AM ET Company Participants Ronnie Speight - Senior Vice President, Investor Relations Alistair Macdonald - Chief Executive Officer Jason Meggs - Chief Financial Officer Paul Colvin - President, Clinical Solution...
Image source: The Motley Fool. Syneos Health, Inc. (NASDAQ: SYNH) Q3 2020 Earnings Call Oct 29, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Syneos Health, Inc. (SYNH) Q3 2020 Earnings Call Transcript
News, Short Squeeze, Breakout and More Instantly...
Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S. PR Newswire JERSEY CITY, N.J. , April 29, 2024 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) is celebrating its eight-year anniversary of being established in th...
Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting PR Newswire Presentations span Parkinson's disease and ALS clinical and real-world evidence Oral platform sessions will highlight r...
Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone) PR Newswire Orphan Drug Exclusivity recognized for RADICAVA ORS based on major contribution to patient care JERSEY CITY, N.J. ...